Zhao Lin-shuang, Liao Yu-hua, Xiang Guang-da, Wang Min, Zhou Zi-hua, Hou Jie, Le Ling, Xu Lin
Department of Endocrinology Wuhan General Hospital of GuangZhou Military Region, Wuhan 430070, China.
Zhonghua Xin Xue Guan Bing Za Zhi. 2006 May;34(5):407-10.
To explore the role of the autoantibodies against M(2)-muscarinic receptor (M(2)-receptor), beta(1)-adrenergic receptor (beta(1)-receptor) in the development of diabetic with refractory hypertension.
Serum autoantibodies against M(2) and beta(1) were detected by ELISA using synthesized epitopes of the second extracellular loop of M(2) receptor (169 - 193) and beta(1) receptor (197 - 222) in healthy controls (n = 40), diabetic patients (n = 62), diabetic patients with non-refractory hypertension (n = 55) and diabetic patients with refractory hypertension (n = 81).
The positive rates of the autoantibodies against M(2) receptor and beta(1) receptor were similar among healthy controls (15.0% and 17. 5%), diabetes mellitus patients (17.7% and 14.5%) and diabetic patients with non-refractory hypertension (16.4% and 12.7%) but are significantly higher in diabetic patients with refractory hypertension (64.2% and 55.6%, P < 0.01 vs. other 3 groups).
This finding suggests that autoimmune mechanisms might play a role in the pathogenesis of diabetic patients with refractory hypertension.
探讨抗M（2）-毒蕈碱受体（M（2）-受体）、β（1）-肾上腺素能受体（β（1）-受体）自身抗体在糖尿病合并难治性高血压发病中的作用。
采用酶联免疫吸附测定法（ELISA），使用合成的M（2）受体（169 - 193）和β（1）受体（197 - 222）细胞外环表位，检测健康对照者（n = 40）、糖尿病患者（n = 62）、糖尿病合并非难治性高血压患者（n = 55）及糖尿病合并难治性高血压患者（n = 81）血清中抗M（2）和β（1）的自身抗体。
健康对照者、糖尿病患者及糖尿病合并非难治性高血压患者中，抗M（2）受体和β（1）受体自身抗体的阳性率相似（分别为15.0%和17.5%、17.7%和14.5%、16.4%和12.7%），但糖尿病合并难治性高血压患者的阳性率显著更高（分别为64.2%和55.6%，与其他3组相比P < 0.01）。
该研究结果提示自身免疫机制可能在糖尿病合并难治性高血压的发病机制中起作用。
